Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6995617 | 0.94 | TAAR1 (0.44) | TAAR1GAAKDM4EHPGDHTT | |
| SCHEMBL7489573 | 0.79 | TAAR1 (0.49) | TAAR1GAAKDM4EHPGDHTT | |
| SCHEMBL9004833 | 0.79 | TAAR1 (0.49) | TAAR1GAAKDM4EHPGDHTT | |
| SCHEMBL9004827 | 0.79 | TAAR1 (0.49) | TAAR1GAAKDM4EHPGDHTT | |
| SCHEMBL16521477 | 0.76 | KMO (0.58) | HTTALDH1A1TSHR | |
| SCHEMBL11374054 | 0.76 | KMO (0.58) | HTTALDH1A1TSHR | |
| SCHEMBL8775309 | 0.76 | KMO (0.58) | HTTALDH1A1TSHR | |
| SCHEMBL3321898 | 0.76 | TAAR1 (0.35) | TAAR1GAAKDM4EHPGDHTT | |
| SCHEMBL9420034 | 0.75 | CES1 (0.43) | KDM4EHTTALDH1A1POLBKMT2A | |
| SCHEMBL10905952 | 0.74 | ALDH1A1 (0.72) | TAAR1GAAKDM4EHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199934-B2 | Alpha-hydroxyketones | BASF SE (DE) | 2015-12-01 | — | — | US | disclosed |
| EP-2129659-B1 | ALPHA-HYDROXYKETONES | BASF SE (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | IGM GROUP B.V. (NL) | 2010-04-29 | — | — | US | disclosed |
| EP-2129659-A1 | ALPHA-HYDROXYKETONES | BASF SE (DE) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008122504-A1 | ALPHA-HYDROXYKETONES | BASF SE (CH) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | C9, C1R, CBR3 | TAAR1 1580/4885GAA 4240/4885KDM4E 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.